Skip To Content
JEWISH. INDEPENDENT. NONPROFIT.
Israel News

Israelis Might Soon Get Their Pot at the Prescription Counter

If Health Minister Yaakov Litzman has his way, Israelis might soon be able to get pot along with their aspirin at the local drugstore. Pending regulations from the Health Ministry, Israel’s biggest pharmacy conglomerate will dispense medical marijuana at its hundreds of locations, according to a report in Ha’aretz.

Israel currently allows sick people to purchase marijuana directly from growers once they have a prescription. But they have to go to a distribution center or sign up for home delivery to receive the product. If the government’s talks with the chain Super-Pharm pan out, then patients could pick up their pot with their other medications. Pharmacists might also be allowed to prescribe the substance to people on the spot.

Health Minister Yaakov Litzman, of the Haredi United Torah Judaism party, first announced plans for the move in a session of the Knesset last year.

“Today pharmacies give out all kind of drugs, including narcotics such as morphine, and it’s done in a perfectly orderly fashion. So marijuana will be handled the same way,” he said. “It will be prescribed and monitored by the same standards as other medications.”

Litzman, who heads the United Torah Judaism party, said the move would ease pressure on the overcrowded medical marijuana dispensaries that struggle to serve thousands of Israelis prescribed the drug.

Litzman’s plan was praised at the time by Tamar Zandberg, a member of the leftwing Meretz party – a rare occurrence as her and Litzman’s factions are on opposite ends of the political spectrum.

“We heard a revolutionary statement on this issue for the first time in several years,” she said. “This is huge news.”

Israel has become an epicenter of medical research into cannabis, with scientists working to create a version of the drug that gives patients its benefits — like reducing inflammation and relieving pain — absent the use of the active ingredients that make recreational users high.

A March report in Arutz Sheva noted that almost two dozen Israeli universities now have research centers for cannabis, and new startups are being launched around the country to refine its production and use.

American tobacco company Phillip Morris even invested $20 million in Syke, an Israeli company that develops medical marijuana inhalers.

According to government statistics, around 27,000 people were treated with medical marijuana last year.

Micki Ofer, a former head of the Pharmaceutical Society of Israel who has been involved in Litzman’s planning efforts, told Ha’aretz that the new rule would send medical use of marijuana soaring.

“After the program comes into effect and more doctors are certified to issue prescriptions, the number of patients using the plant will skyrocket to around 100,000.”

Contact Daniel J. Solomon at solomon@forward.com or on Twitter @DanielJSolomon

A message from our CEO & publisher Rachel Fishman Feddersen

I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism during this critical time.

We’ve set a goal to raise $260,000 by December 31. That’s an ambitious goal, but one that will give us the resources we need to invest in the high quality news, opinion, analysis and cultural coverage that isn’t available anywhere else.

If you feel inspired to make an impact, now is the time to give something back. Join us as a member at your most generous level.

—  Rachel Fishman Feddersen, Publisher and CEO

With your support, we’ll be ready for whatever 2025 brings.

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines. You must credit the Forward, retain our pixel and preserve our canonical link in Google search.  See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at editorial@forward.com, subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.

Exit mobile version